Mickaël Hiligsmann (M.J.C.)

Li, N., Majoie, M., Evers, S., Rijkers, K., Gubler, F., Rouhl, R., Lazeron, R., Klarenbeek, P., Laskier-Owens, V., & Hiligsmann, M. (2025). Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands. Journal of Medical Economics, 28(1), 114-123. https://doi.org/10.1080/13696998.2024.2443338

Raskin, N., Hiligsmann, M., Rebutoc, A. R., Bansback, N., Boonen, A., Buchbinder, R., Falahee, M., Fraenkel, L., Marshall, D. A., Maxwell, L., Nieuwlaat, R., Proulx, L., Saadat, P., Shea, B., Tugwell, P., Wiercioch, W., Beaton, D., Richards, P., Schünemann, H., ... Hazlewood, G. S. (2025). Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors. Seminars in Arthritis and Rheumatism, 74, Article 152769. https://doi.org/10.1016/j.semarthrit.2025.152769

Nagendra, L., Chandran, M., & Hiligsmann, M. (2025). The economic benefits of fracture prevention. Expert Review of Pharmacoeconomics & Outcomes Research. Advance online publication. https://doi.org/10.1080/14737167.2025.2539838

Nagendra, L., Agarwal, K., Patra, S., Bhattacharya, S., Gupta, L., Talwar, N., Rao, A., Gupta, A., Kamrul-Hasan, A. B. M., Dutta, D., Hiligsmann, M., & Chandran, M. (2025). Optimizing Bone Health in Diabetes: Strategies for Fracture Risk Reduction in Public Healthcare. Current Diabetes Reports, 25(1), Article 43. https://doi.org/10.1007/s11892-025-01599-x

Hinzpeter, E.-L., Kairies-Schwarz, N., Beaudart, C., Douxfils, J., Nayak, D., & Hiligsmann, M. (2025). A Systematic Review of Discrete Choice Experiments on Preferences for COVID-19 Vaccinations. The Patient: patient-centered outcomes research. Advance online publication. https://doi.org/10.1007/s40271-025-00753-7

Cheung, K. L., & Hiligsmann, M. (2025). Collaborative economic tools for prevention strategies: case of the EQUIPT model. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2529363

Reith, E., Maas, L., Joos, A., Heikkinen, I., De Iaco, M., & Hiligsmann, M. (2025). Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries. Expert Review of Pharmacoeconomics & Outcomes Research. Advance online publication. https://doi.org/10.1080/14737167.2025.2530622

Wouterse, B., Santos, J. V., & Hiligsmann, M. (2025). Future directions for the economics of prevention. Expert Review of Pharmacoeconomics & Outcomes Research, 25(6), 841-844. https://doi.org/10.1080/14737167.2025.2498665

Maas, L., Contreras-Meca, C., Ghezzo, S., Belmans, F., Corsi, A., Cant, J., Vos, W., Bobowicz, M., Rygusik, M., Laski, D. K., Annemans, L., Hiligsmann, M., Lambin, P., & Woodruff, H. (2025). Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy. Journal of Medical Economics, 28(1), 1023-1036. Advance online publication. https://doi.org/10.1080/13696998.2025.2525006

Janssen, L. E. F., Hiligsmann, M., Timmer, C., van der Ploeg, L. M. C., Kerckhove, K. V., Cox, T., Heras, J. D. L., Cassiman, D., & Brouwers, M. C. G. J. (2025). Treatment preferences of adult patients with hereditary fructose intolerance: A discrete choice experiment. Molecular Genetics and Metabolism, 145(4), Article 109169. https://doi.org/10.1016/j.ymgme.2025.109169